{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T03:32:26Z","timestamp":1782790346149,"version":"3.54.5"},"reference-count":59,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.semradonc.2024.10.005","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T06:03:53Z","timestamp":1733983433000},"page":"99-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["The Role of Radiotherapy in Lymphoma Patients Undergoing CAR T Therapy: Past, Present, and Future"],"prefix":"10.1016","volume":"35","author":[{"given":"David G.","family":"Wallington","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon S.","family":"Imber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Scordo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semradonc.2024.10.005_bib0001","article-title":"Estimation of eligibility for and response to CAR-T therapy in the United States","author":"Haslam","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.semradonc.2024.10.005_bib0002","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1182\/hematology.2022000332","article-title":"Sequencing therapy in relapsed DLBCL","volume":"2022","author":"Flowers","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.semradonc.2024.10.005_bib0003","unstructured":"Axicabtagene ciloleucel receives US FDA approval as second-line treatment for large B-cell lymphoma. Accessed February 8, 2024. https:\/\/lymphomahub.com\/medical-information\/axicabtagene-ciloleucel-receives-us-fda-approval-as-second-line-treatment-for-large-b-cell-lymphoma"},{"issue":"27","key":"10.1016\/j.semradonc.2024.10.005_bib0004","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.semradonc.2024.10.005_bib0005","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1016\/j.semradonc.2024.10.005_bib0006","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.semradonc.2024.10.005_bib0007","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.semradonc.2024.10.005_bib0008","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"10343","key":"10.1016\/j.semradonc.2024.10.005_bib0009","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.semradonc.2024.10.005_bib0010","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.semradonc.2024.10.005_bib0011","doi-asserted-by":"crossref","first-page":"7393","DOI":"10.1182\/blood-2023-186984","article-title":"Real-World Analysis of Barriers to Timely Administration of Chimeric Antigen Receptor T-Cell (CART) Therapy in Diffuse Large B-Cell Lymphoma (DLBCL)","volume":"142","author":"Ehsan","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.semradonc.2024.10.005_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.semradonc.2024.10.005_bib0013","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1182\/blood-2019-127490","article-title":"A multicenter retrospective analysis of clinical outcomes, toxicities, and patterns of use in institutions utilizing commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B-cell lymphomas","volume":"134","author":"Riedell","year":"2019","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.semradonc.2024.10.005_bib0014","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/cancers13194789","article-title":"Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed\/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience","volume":"13","author":"Casadei","year":"2021","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.semradonc.2024.10.005_bib0015","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1002\/cam4.3881","article-title":"Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma","volume":"10","author":"Iacoboni","year":"2021","journal-title":"Cancer Med"},{"issue":"9","key":"10.1016\/j.semradonc.2024.10.005_bib0016","doi-asserted-by":"crossref","first-page":"581.e1","DOI":"10.1016\/j.jtct.2022.05.026","article-title":"Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.semradonc.2024.10.005_bib0017","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.semradonc.2024.10.005_bib0018","first-page":"349","article-title":"GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany","volume":"140","author":"Bethge","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.semradonc.2024.10.005_bib0019","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.ijrobp.2019.05.065","article-title":"Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma","volume":"105","author":"Sim","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"27","key":"10.1016\/j.semradonc.2024.10.005_bib0020","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.semradonc.2024.10.005_bib0021","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","article-title":"Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma","volume":"4","author":"Pinnix","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.semradonc.2024.10.005_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1205836","article-title":"Radiation for hematologic malignancies: from cell killing to immune cell priming","volume":"13","author":"Dabaja","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.semradonc.2024.10.005_bib0023","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.radonc.2021.11.031","article-title":"Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?","volume":"166","author":"Saifi","year":"2022","journal-title":"Radiother Oncol"},{"issue":"6","key":"10.1016\/j.semradonc.2024.10.005_bib0024","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061747","article-title":"Long-Term Follow-Up of Bridging Therapies Prior to CAR T-Cell Therapy for Relapsed\/Refractory Large B Cell Lymphoma","volume":"15","author":"Ladbury","year":"2023","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.semradonc.2024.10.005_bib0025","doi-asserted-by":"crossref","first-page":"e483","DOI":"10.1016\/j.ijrobp.2023.06.1708","article-title":"Outcomes with Bridging Radiation Therapy Prior to CAR-T Cell Therapy in Pts with Aggressive B Cell Lymphomas","volume":"117","author":"Manzar","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.semradonc.2024.10.005_bib0026","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/j.ijrobp.2023.06.333","article-title":"Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas: An ILROG Multi-Institutional Study","volume":"117","author":"Yegya-Raman","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.semradonc.2024.10.005_bib0027","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/bjh.19453","article-title":"Outcome and feasibility of radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T in the UK","volume":"205","author":"Kuhnl","year":"2024","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.semradonc.2024.10.005_bib0028","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.3324\/haematol.2023.283311","article-title":"Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma","volume":"108","author":"Saifi","year":"2023","journal-title":"Haematologica"},{"issue":"2, Supplement","key":"10.1016\/j.semradonc.2024.10.005_bib0029","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.ijrobp.2023.06.334","article-title":"Phase I Trial of \u2018Re-Priming\u2019 Radiation Therapy for Relapsed\/Refractory Non-Hodgkin Lymphoma Patients in Incomplete Response after Chimeric Antigen Receptor T-Cell (CAR-T) Therapy","volume":"117","author":"Kumar","year":"2023","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"issue":"1","key":"10.1016\/j.semradonc.2024.10.005_bib0030","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/bjh.16541","article-title":"Early experience using salvage radiotherapy for relapsed\/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy","volume":"190","author":"Imber","year":"2020","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.semradonc.2024.10.005_bib0031","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.ijrobp.2022.07.438","article-title":"Outcomes of Salvage Radiotherapy in Refractory or Relapsed High-Grade B-Cell Lymphoma Patients Treated with Commercial CAR T-Cell Therapy","volume":"114","author":"Ababneh","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.semradonc.2024.10.005_bib0032","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/CJI.0000000000000284","article-title":"Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed\/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden","volume":"43","author":"Qu","year":"2020","journal-title":"J Immunother"},{"issue":"1","key":"10.1016\/j.semradonc.2024.10.005_bib0033","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijrobp.2020.05.014","article-title":"Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma","volume":"108","author":"Wright","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Supplement 1","key":"10.1016\/j.semradonc.2024.10.005_bib0034","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1182\/blood-2023-187763","article-title":"Dynamics of Radiomic Features Following Bridging Therapy Determine CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy Outcome","volume":"142","author":"Hubbeling","year":"2023","journal-title":"Blood"},{"issue":"2S","key":"10.1016\/j.semradonc.2024.10.005_bib0035","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.ijrobp.2023.06.336","article-title":"Prognostic significance of positron emission tomography delta radiomics following bridging therapy in patients with large B-cell lymphoma undergoing CAR T-cell therapy","volume":"117","author":"Ladbury","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.semradonc.2024.10.005_bib0036","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41408-023-00895-7","article-title":"Metabolic PET\/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity","volume":"13","author":"Breen","year":"2023","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.semradonc.2024.10.005_bib0037","doi-asserted-by":"crossref","first-page":"259.e1","DOI":"10.1016\/j.jtct.2022.12.021","article-title":"Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed\/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy","volume":"29","author":"Hubbeling","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"14","key":"10.1016\/j.semradonc.2024.10.005_bib0038","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.semradonc.2024.10.005_bib0039","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/2159-8290.CD-19-0813","article-title":"Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction","volume":"10","author":"Singh","year":"2020","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.semradonc.2024.10.005_bib0040","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1182\/bloodadvances.2022009019","article-title":"Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma","volume":"7","author":"Roddie","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.semradonc.2024.10.005_bib0041","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.ijrobp.2022.07.490","article-title":"Cytokine release syndrome and neurotoxicity after chimeric antigen receptor T-cell therapy for relapsed\/refractory B-cell lymphoma: Is there an association with bridging radiotherapy?","volume":"114","author":"Yegya-Raman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.semradonc.2024.10.005_bib0042","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.ijrobp.2021.06.038","article-title":"Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy","volume":"111","author":"Figura","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.semradonc.2024.10.005_bib0043","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41419-023-05829-6","article-title":"Radiation therapy improves CAR T cell activity in acute lymphoblastic leukemia","volume":"14","author":"Sugita","year":"2023","journal-title":"Cell Death Dis"},{"issue":"11","key":"10.1016\/j.semradonc.2024.10.005_bib0044","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.ymthe.2018.09.008","article-title":"Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape","volume":"26","author":"DeSelm","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.semradonc.2024.10.005_bib0045","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1182\/blood-2023-185216","article-title":"Low Dose Total Body Irradiation Improves CD19 CAR-T Expansion, Persistence, and Trafficking, Leading to Enhanced Efficacy in Large B-Cell Lymphoma","volume":"142","author":"Alhomoud","year":"2023","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.semradonc.2024.10.005_bib0046","first-page":"940","article-title":"Hypoxia-Directed Treatment of Human Papillomavirus\u2013Related Oropharyngeal Carcinoma","volume":"42","author":"Lee","year":"2024","journal-title":"J Clin Orthod"},{"issue":"11","key":"10.1016\/j.semradonc.2024.10.005_bib0047","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1007\/s00259-023-06296-z","article-title":"Hypoxia-specific imaging in patients with lymphoma undergoing CAR-T therapy","volume":"50","author":"Banerjee","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.semradonc.2024.10.005_bib0048","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"issue":"103941","key":"10.1016\/j.semradonc.2024.10.005_bib0049","article-title":"Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion","volume":"77","author":"Gumber","year":"2022","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.semradonc.2024.10.005_bib0050","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41388-020-01501-x","article-title":"Counteracting CAR T cell dysfunction","volume":"40","author":"Poorebrahim","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.semradonc.2024.10.005_bib0051","article-title":"Salvage radiotherapy for relapsed\/refractory non-Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy","volume":"39","author":"Yegya-Raman","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"issue":"12","key":"10.1016\/j.semradonc.2024.10.005_bib0052","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/17474086.2022.2147919","article-title":"Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes","volume":"15","author":"Figura","year":"2022","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"10.1016\/j.semradonc.2024.10.005_bib0053","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jtct.2022.10.026","article-title":"Allogeneic hematopoietic cell transplantation after chimeric antigen receptor T cell therapy in large B cell lymphoma","volume":"29","author":"Fried","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.semradonc.2024.10.005_bib0054","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065688","article-title":"CAR T-cell persistence correlates with improved outcome in patients with B-cell lymphoma","volume":"24","author":"Wittibschlager","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"13","key":"10.1016\/j.semradonc.2024.10.005_bib0055","first-page":"1832","article-title":"Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy","volume":"137","author":"Spiegel","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.semradonc.2024.10.005_bib0056","article-title":"Radiation Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma: What Is the Right Regimen for Palliation?","volume":"7","author":"Wright","year":"2022","journal-title":"Adv Radiat Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2024.10.005_bib0057","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Med"},{"issue":"1127","key":"10.1016\/j.semradonc.2024.10.005_bib0058","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210098","article-title":"The Current and Future Role of Radiation Therapy in the Era of CAR T-cell Salvage","volume":"94","author":"DeSelm","year":"2021","journal-title":"Br J Radiol"},{"issue":"3","key":"10.1016\/j.semradonc.2024.10.005_bib0059","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1016\/j.ijrobp.2018.06.306","article-title":"Tandem Induction Radiation and Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma","volume":"102","author":"Arscott","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429624000900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429624000900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T13:59:49Z","timestamp":1734011989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429624000900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1053429624000900"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2024.10.005","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Radiotherapy in Lymphoma Patients Undergoing CAR T Therapy: Past, Present, and Future","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2024.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}